{"id":583821,"date":"2026-06-02T07:25:29","date_gmt":"2026-06-02T07:25:29","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/?p=583775"},"modified":"2026-06-15T11:18:30","modified_gmt":"2026-06-15T11:18:30","slug":"the-hidden-complexity-of-pharmaceutical-competitive-intelligence-data","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/ko\/blog\/the-hidden-complexity-of-pharmaceutical-competitive-intelligence-data\/","title":{"rendered":"\uc65c \uc2e0\uc57d\uc740 \ud55c\uac1c\uc758 \uc774\ub984\ub9cc\uc73c\ub85c \uc124\uba85\ub418\uc9c0 \uc54a\uc744\uae4c\uc694?"},"content":{"rendered":"<p>2018\ub144 3\uc6d4, Celgene\uc740 90\uc5b5 \ub2ec\ub7ec \uaddc\ubaa8\ub85c Juno Therapeutics\ub97c \uc778\uc218\ud558\uba70 \ub2f9\uc2dc JCAR017\uc73c\ub85c \uc54c\ub824\uc9c4 CAR-T \uc138\ud3ec \uce58\ub8cc\uc81c \ud504\ub85c\uadf8\ub7a8\uc758 \uad8c\ub9ac\ub97c \ud655\ubcf4\ud588\uc2b5\ub2c8\ub2e4. \uadf8\ub9ac\uace0 1\ub144 \ub4a4\uc778 2019\ub144, Bristol Myers Squibb\uc774 Celgene\uc744 740\uc5b5 \ub2ec\ub7ec\uc5d0 \uc778\uc218\ud558\uba74\uc11c \ud574\ub2f9 \uc790\uc0b0 \uc5ed\uc2dc \ud568\uaed8 \ub118\uc5b4\uac14\uc2b5\ub2c8\ub2e4. \uc774\ud6c4 2021\ub144 FDA\ub294 \uac1c\ubc1c \ub2e8\uacc4\uc5d0\uc11c\ub294 \uc775\uc219\ud558\uc9c0 \uc54a\uc558\ub358 \uc774\ub984\uc778 lisocabtagene maraleucel\uc744 \uc2b9\uc778\ud588\uace0, \ud604\uc7ac\ub294 Breyanzi\ub77c\ub294 \ube0c\ub79c\ub4dc\uba85\uc73c\ub85c \ud310\ub9e4\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<sup>1, 2, 3, 4<\/sup><\/p>\n<p>\uc624\ub298\ub0a0 Breyanzi\ub294 5\uac1c \uc554\uc885\uc5d0 \ub300\ud574 \uc2b9\uc778\ub41c \uc720\uc77c\ud55c CAR-T \uc138\ud3ec \uce58\ub8cc\uc81c\uc785\ub2c8\ub2e4. \ub3d9\uc2dc\uc5d0 \uc774 \uc0ac\ub840\ub294 \uc65c \uc2e0\ub8b0\ud560 \uc218 \uc788\ub294 \uc81c\uc57d \uacbd\uc7c1 \uc815\ubcf4 \ub370\uc774\ud130\ubca0\uc774\uc2a4\ub97c \uad6c\ucd95\ud558\ub294 \uac83\uc774 \uc5b4\ub824\uc6b4\uc9c0, \uadf8\ub9ac\uace0 \ub2e8\uc21c \ub370\uc774\ud130 \uc218\uc9d1\uacfc \uc804\ubb38\uc801\uc778 \ub370\uc774\ud130 \ud050\ub808\uc774\uc158 \uc0ac\uc774\uc5d0 \uc5b4\ub5a4 \ucc28\uc774\uac00 \uc788\ub294\uc9c0\ub97c \uc798 \ubcf4\uc5ec\uc90d\ub2c8\ub2e4.<sup>5<\/sup><\/p>\n<h3><strong>\uc65c \uc2e0\uc57d\uc740 \ud55c\uac1c\uc758 \uc774\ub984\ub9cc\uc73c\ub85c \uc124\uba85\ub418\uc9c0 \uc54a\uc744\uae4c\uc694?<\/strong><\/h3>\n<p>\uc2e0\uc57d\uc740 \uc5f0\uad6c\uc2e4\uc5d0\uc11c \uc2dc\uc791\ud574 \uc784\uc0c1 \uac1c\ubc1c, \uae30\uc5c5 \uc778\uc218\ud569\ubcd1, \uc0c1\uc5c5\ud654\uc5d0 \uc774\ub974\uae30\uae4c\uc9c0 \uae34 \uc5ec\uc815\uc744 \uac70\uce69\ub2c8\ub2e4. \uadf8 \uacfc\uc815\uc5d0\uc11c \ud558\ub098\uc758 \uc57d\ubb3c\uc740 \uc5ec\ub7ec \uc774\ub984\uacfc \ucf54\ub4dc\uba85\uc744 \uac16\uac8c \ub429\ub2c8\ub2e4. \ubb38\uc81c\ub294 \uc774 \ubaa8\ub4e0 \uc774\ub984\uc774 \uac01\uac01\uc758 \ub9e5\ub77d\uc5d0\uc11c\ub294 \uc815\ud655\ud558\uc9c0\ub9cc \uc11c\ub85c \uc790\ub3d9\uc73c\ub85c \uc5f0\uacb0\ub418\uc9c0 \uc54a\ub294\ub2e4\ub294 \uc810\uc785\ub2c8\ub2e4.<\/p>\n<p>\uc608\ub97c \ub4e4\uc5b4 lisocabtagene maraleucel\uc740 \uac1c\ubc1c \uacfc\uc815\uc5d0\uc11c \ub2e4\uc74c\uacfc \uac19\uc740 \uc774\ub984\uc73c\ub85c \ubd88\ub838\uc2b5\ub2c8\ub2e4.<\/p>\n<ul>\n<li><strong>Lisocabtagene maraleucel<\/strong>-\uaddc\uc81c \ubb38\uc11c\uc640 \ud559\uc220 \ub17c\ubb38\uc5d0\uc11c \uc0ac\uc6a9\ud558\ub294 \uad6d\uc81c\uc77c\ubc18\uba85(INN)<sup>1<\/sup><sup>6<\/sup><\/li>\n<li><strong>Breyanzi<\/strong> -\uc0c1\uc5c5\ud654 \uc774\ud6c4 \uc0ac\uc6a9\ub418\ub294 \ube0c\ub79c\ub4dc\uba85<sup>7<\/sup><\/li>\n<li><strong>Liso-cel<\/strong> &#8211; \ud559\ud68c \ubc1c\ud45c\uc640 \uc784\uc0c1 \ubb38\ud5cc\uc5d0\uc11c \ub110\ub9ac \uc0ac\uc6a9\ub418\ub294 \uc57d\uce6d<sup>8<\/sup><\/li>\n<li><strong>JCAR017<\/strong> &#8211; Juno Therapeutics \uc2dc\uc808\uc758 \uc5f0\uad6c \ucf54\ub4dc\uba85<sup>2, 9<\/sup><\/li>\n<li><strong>BMS-986387<\/strong> &#8211; Celgene \uc778\uc218 \uc774\ud6c4 \ubd80\uc5ec\ub41c \uac1c\ubc1c \ucf54\ub4dc\uba85<\/li>\n<li><strong>Anti-CD19 CAR T-cell therapy<\/strong> &#8211; \ucd08\uae30 \ud2b9\ud5c8\uc640 \uc804\uc784\uc0c1 \uc5f0\uad6c\uc5d0\uc11c \uc0ac\uc6a9\ub41c \uae30\uc220\uc801 \uba85\uce6d<\/li>\n<li><strong>SCRI-CAR19v1<\/strong> &#8211; \uc77c\ubd80 \uc5f0\uad6c\uc790 \uc8fc\ub3c4 \uc5f0\uad6c\uc5d0\uc11c \uc0ac\uc6a9\ub41c \uad6c\uc131\uccb4 \uba85\uce6d<\/li>\n<\/ul>\n<p>\uc5b4\ub5a4 \uc560\ub110\ub9ac\uc2a4\ud2b8\ub294 &#8220;JCAR017&#8243;\uc744 \uac80\uc0c9\ud558\uace0, \ub2e4\ub978 \uc560\ub110\ub9ac\uc2a4\ud2b8\ub294 &#8220;Breyanzi&#8221;\ub97c \uac80\uc0c9\ud560 \uc218 \uc788\uc2b5\ub2c8\ub2e4. \ud558\uc9c0\ub9cc \ub458 \ub2e4 \ub3d9\uc77c\ud55c \uce58\ub8cc\uc81c\ub97c \ucc3e\uace0 \uc788\ub294 \uac83\uc785\ub2c8\ub2e4. \uc774 \uc5f0\uacb0\uace0\ub9ac\ub97c \ucc3e\uae30 \uc704\ud574\uc11c\ub294 \ub2e8\uc21c\ud55c \ud0a4\uc6cc\ub4dc \uac80\uc0c9\ub9cc\uc73c\ub85c\ub294 \ubd80\uc871\ud569\ub2c8\ub2e4. \uc2e0\uc57d \uac1c\ubc1c \uacfc\uc815\uacfc \uc0b0\uc5c5 \uad6c\uc870\ub97c \uc774\ud574\ud558\ub294 \uc804\ubb38\uac00\ub4e4\uc774 \uad6c\ucd95\ud55c \uccb4\uacc4\uc801\uc778 \ub370\uc774\ud130 \uc5f0\uacb0 \uad6c\uc870\uac00 \ud544\uc694\ud569\ub2c8\ub2e4.<\/p>\n<h3><strong>\ud68c\uc0ac \uc774\ub984\ub3c4 \ub04a\uc784\uc5c6\uc774 \ubcc0\ud654\ud569\ub2c8\ub2e4.<\/strong><\/h3>\n<p>\ubcf5\uc7a1\uc131\uc740 \uc57d\ubb3c\uba85\uc5d0\uc11c \ub05d\ub098\uc9c0 \uc54a\uc2b5\ub2c8\ub2e4. Breyanzi\uc758 \uac1c\ubc1c \uc774\ub825\uc744 \uc0b4\ud3b4\ubcf4\uba74, \ub3d9\uc77c\ud55c \ud504\ub85c\uadf8\ub7a8\uc774 \uc5ec\ub7ec \ud68c\uc0ac\uc758 \uc190\uc744 \uac70\uce58\uba70 \uc18c\uc720\uad8c\uc774 \ubc14\ub00c\uc5c8\uc2b5\ub2c8\ub2e4. \uadf8\ub9ac\uace0 \uadf8 \uacfc\uc815\uc5d0\uc11c \ud68c\uc0ac\uba85 \uc5ed\uc2dc \ub2e4\uc591\ud55c \ud615\ud0dc\ub85c \uae30\ub85d\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc6d0 \uac1c\ubc1c\uc0ac\uc778 Juno Therapeutics\ub294 \uc790\ub8cc\uc5d0 \ub530\ub77c Juno Therapeutics Inc., Juno Therapeutics LLC, Juno (Celgene) \ub4f1 \ub2e4\uc591\ud55c \uc774\ub984\uc73c\ub85c \ub4f1\uc7a5\ud569\ub2c8\ub2e4. \uc774\ud6c4 Juno\ub97c \uc778\uc218\ud55c Celgene \uc5ed\uc2dc Celgene, Celgene Corporation, Celgene Corp., Celgene Inc., Celgene\/BMS, CELG \ub4f1 \uc5ec\ub7ec \ud615\ud0dc\ub85c \uae30\ub85d\ub429\ub2c8\ub2e4. 2019\ub144 Celgene\uc744 740\uc5b5 \ub2ec\ub7ec\uc5d0 \uc778\uc218\ud558\uba70 \ud604\uc7ac \ud574\ub2f9 \uc790\uc0b0\uc744 \ubcf4\uc720\ud558\uace0 \uc788\ub294 Bristol Myers Squibb \uc5ed\uc2dc \uc608\uc678\ub294 \uc544\ub2d9\ub2c8\ub2e4. \ubb38\uc11c\uc5d0 \ub530\ub77c Bristol Myers Squibb Company, Bristol-Myers Squibb \ub610\ub294 \uac04\ub2e8\ud788 BMS\ub85c \ud45c\uae30\ub418\uae30\ub3c4 \ud569\ub2c8\ub2e4.<sup>4,<\/sup> <sup>10, 11,<\/sup> <sup>12<\/sup><\/p>\n<p>\uc5b4\ub5a4 \uae30\uc5c5\uc774 \ud2b9\uc815 \ud504\ub85c\uadf8\ub7a8\uc744 \uac1c\ubc1c\ud588\ub294\uc9c0 \uc815\ud655\ud788 \ud30c\uc545\ud558\ub824\uba74 \uc57d\ubb3c\uba85\ubfd0 \uc544\ub2c8\ub77c \uae30\uc5c5\uba85\uacfc \uc778\uc218\ud569\ubcd1 \uc774\ub825\uae4c\uc9c0 \ud568\uaed8 \ucd94\uc801\ud574\uc57c \ud569\ub2c8\ub2e4. \uc774 \uc911 \ud558\ub098\ub77c\ub3c4 \uc5f0\uacb0\uc774 \ub204\ub77d\ub418\uba74 \uac1c\ubc1c \uc774\ub825\uc774 \uc65c\uace1\ub418\uac70\ub098 \uacbd\uc7c1 \ud658\uacbd \ubd84\uc11d \uacb0\uacfc\uac00 \ub2ec\ub77c\uc9c8 \uc218 \uc788\uc73c\uba70, \uc2ec\uc9c0\uc5b4 \uc778\uc218 \uc790\uc0b0\uc758 \uac00\uce58 \ud3c9\uac00\uc5d0\ub3c4 \uc601\ud5a5\uc744 \uc904 \uc218 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<h3><strong>\uc801\uc751\uc99d\uae4c\uc9c0 \uace0\ub824\ud558\uba70 \ubcf5\uc7a1\uc131\uc774 \ub354 \uc99d\ud3ed\ub429\ub2c8\ub2e4.<\/strong><\/h3>\n<p>Lisocabtagene maraleucel\uc740 2021\ub144 \uc774\ud6c4 FDA\ub85c\ubd80\ud130 \ucd1d 5\uac1c \uc801\uc751\uc99d\uc5d0 \ub300\ud55c \uc2b9\uc778\uc744 \ud68d\ub4dd\ud588\uc2b5\ub2c8\ub2e4.:<sup>1, 5<\/sup><\/p>\n<ol>\n<li>\ub300\ud615 B\uc138\ud3ec \ub9bc\ud504\uc885 (\ucd5c\ucd08 \uc2b9\uc778 \uc801\uc751\uc99d, 2021\ub144 2\uc6d4)<\/li>\n<li>\ub9cc\uc131 \ub9bc\ud504\uad6c\uc131 \ubc31\ud608\ubcd1\/\uc18c\ub9bc\ud504\uad6c\uc131 \ub9bc\ud504\uc885(CLL\/SLL) \u2013 2024\ub144 3\uc6d4<sup>8<\/sup><\/li>\n<li>\uc5ec\ud3ec\uc131 \ub9bc\ud504\uc885(Follicular lymphoma) \u2013 2024\ub144 5\uc6d4<sup>6<\/sup><\/li>\n<li>\uc678\ud22c\uc138\ud3ec \ub9bc\ud504\uc885(Mantle cell lymphoma) \u2013 2024\ub144 5\uc6d4<sup>8<\/sup><\/li>\n<li>\ubcc0\uc5f0\ubd80 \ub9bc\ud504\uc885(Marginal zone lymphoma) \u2013 2025\ub144 12\uc6d4<sup>5<\/sup><\/li>\n<\/ol>\n<p>\uc801\uc751\uc99d\ub9c8\ub2e4 \uc0ac\uc6a9\ub418\ub294 \uc6a9\uc5b4\ub3c4 \uc81c\uac01\uac01\uc785\ub2c8\ub2e4. \uc608\ub97c \ub4e4\uc5b4 \ubbf8\ub9cc\uc131 \uac70\ub300 B\uc138\ud3ec \ub9bc\ud504\uc885(Diffuse Large B-cell Lymphoma)\uc740 \ubb38\ud5cc\uc5d0 \ub530\ub77c DLBCL, DLBCL NOS \ub610\ub294 \uacf5\uaca9\uc131 \ube44\ud638\uc9c0\ud0a8 \ub9bc\ud504\uc885(Aggressive Non-Hodgkin Lymphoma)\uc73c\ub85c \ud45c\ud604\ub420 \uc218 \uc788\uc2b5\ub2c8\ub2e4. \uc5ec\ud3ec\uc131 \ub9bc\ud504\uc885(Follicular Lymphoma)\uc740 FL, FNHL, \uc18c\ud3ec \uc911\uc2ec\uc138\ud3ec \ub9bc\ud504\uc885(Small Follicular Center Cell Lymphoma) \ub4f1\uc73c\ub85c \ub098\ud0c0\ub098\uba70, \ubcc0\uc5f0\ubd80 \ub9bc\ud504\uc885(Marginal Zone Lymphoma) \uc5ed\uc2dc MZL, MALT \ub9bc\ud504\uc885(MALT Lymphoma), \uc810\ub9c9\uc5f0\uad00 \ub9bc\ud504\uc870\uc9c1 \ub9bc\ud504\uc885(Mucosa-Associated Lymphoid Tissue Lymphoma) \ub4f1 \ub2e4\uc591\ud55c \uba85\uce6d\uc73c\ub85c \uae30\ub85d\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc5ec\uae30\uc5d0 \ub610 \ud558\ub098\uc758 \ubcf5\uc7a1\uc131\uc774 \uc788\uc2b5\ub2c8\ub2e4. \ubaa8\ub4e0 \uc815\ubcf4 \ucd9c\ucc98\uac00 \ubaa8\ub4e0 \uc801\uc751\uc99d\uc744 \ub2e4\ub8e8\ub294 \uac83\uc740 \uc544\ub2c8\ub77c\ub294 \uc810\uc785\ub2c8\ub2e4. \ucd08\uae30 \ud559\uc220 \ub17c\ubb38\uc740 \ucd5c\ucd08 \uc801\uc751\uc99d\uc778 DLBCL \ud504\ub85c\uadf8\ub7a8\uc5d0 \uc9d1\uc911\ud558\ub294 \uacbd\uc6b0\uac00 \ub9ce\uace0, \uaddc\uc81c\uae30\uad00 \uc81c\ucd9c \uc790\ub8cc\ub294 \uc81c\ucd9c \ub2f9\uc2dc \uc2b9\uc778 \ub300\uc0c1 \ud658\uc790\uad70\uc744 \ubc18\uc601\ud569\ub2c8\ub2e4. \ubc18\uba74 \ud559\ud68c \ucd08\ub85d\uc5d0\uc11c\ub294 \uc218\ub144 \ub4a4 \uc2b9\uc778\uc73c\ub85c \uc774\uc5b4\uc9c8 \uc784\uc0c1\uc2dc\ud5d8 \ucf54\ud638\ud2b8\uac00 \uba3c\uc800 \uc18c\uac1c\ub418\uae30\ub3c4 \ud569\ub2c8\ub2e4. \uacb0\uad6d \uce58\ub8cc\uc81c\uc758 \uc804\uccb4 \uac1c\ubc1c \uc2a4\ud1a0\ub9ac\ub294 \ud769\uc5b4\uc838 \uc788\ub294 \ub370\uc774\ud130 \uc870\uac01\ub4e4\uc744 \uc2dc\uac04\ucd95 \uc704\uc5d0\uc11c \uc5f0\uacb0\ud560 \ub54c \ube44\ub85c\uc18c \ub4dc\ub7ec\ub0a9\ub2c8\ub2e4.<\/p>\n<h3><strong>\ub300\uaddc\ubaa8 \uc81c\uc57d \uc778\ud154\ub9ac\uc804\uc2a4\ub294 \uc5b4\ub5bb\uac8c \uad6c\ud604\ub420\uae4c?<\/strong><\/h3>\n<p>Cortellis Competitive Intelligence\ub294 \uc2e0\uc57d \uac1c\ubc1c \uc804 \uc8fc\uae30\uc5d0 \uac78\uccd0 10\ub9cc 1\ucc9c \uac1c \uc774\uc0c1\uc758 \uac1c\ubc1c \ud30c\uc774\ud504\ub77c\uc778 \uc57d\ubb3c\uacfc 3\ub9cc 2\ucc9c \uac1c \uc774\uc0c1\uc758 \ucd08\uae30 \uc5f0\uad6c \ub2e8\uacc4 \uc790\uc0b0\uc744 \ucd94\uc801\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ub610\ud55c 3,000\uac1c \uc774\uc0c1\uc758 \uc9c8\ud658, 690\ub9cc \uac74 \uc774\uc0c1\uc758 \ud2b9\ud5c8, 31\ub9cc 6\ucc9c \uac1c \uc774\uc0c1\uc758 \uae30\uc5c5 \ud504\ub85c\ud30c\uc77c\uc744 \ud3ec\uad04\uc801\uc73c\ub85c \ubd84\uc11d\ud569\ub2c8\ub2e4. \ud558\uc9c0\ub9cc \uc774\ucc98\ub7fc \ubc29\ub300\ud55c \uaddc\ubaa8\uc758 \ub370\uc774\ud130\ub3c4 \uac01\uac01\uc758 \uc815\ubcf4\uac00 \uc815\ud655\ud558\uac8c \uc5f0\uacb0\ub418\uc5b4 \uc788\uc744 \ub54c \ube44\ub85c\uc18c \uac00\uce58\ub97c \ubc1c\ud718\ud569\ub2c8\ub2e4.<sup>13<\/sup><\/p>\n<p>Cortellis\uc758 \ubaa8\ub4e0 \ub370\uc774\ud130\ub294 \uc138 \uac00\uc9c0 \ud575\uc2ec \uc6d0\uce59\uc5d0 \uae30\ubc18\ud55c \ud050\ub808\uc774\uc158 \uacfc\uc815\uc744 \uac70\uce69\ub2c8\ub2e4.<\/p>\n<p>\uccab\uc9f8, \ud574\ub2f9 \ubd84\uc57c \uc804\ubb38\uac00\ub4e4\uc774 \uc9c1\uc811 \ub2e4\uc591\ud55c \ucd9c\ucc98\ub97c \uac80\ud1a0\ud558\uace0 \uac80\uc99d\ud569\ub2c8\ub2e4. \uc774\ub97c \ud1b5\ud574 \uc790\ub3d9\ud654\ub41c \ub370\uc774\ud130 \uc218\uc9d1\ub9cc\uc73c\ub85c\ub294 \ubc1c\uacac\ud558\uae30 \uc5b4\ub824\uc6b4 \ubaa8\ud638\uc131\uc774\ub098 \ubd88\uc77c\uce58\ub97c \ud574\uc18c\ud569\ub2c8\ub2e4.<\/p>\n<p>\ub458\uc9f8, \uc77c\uad00\ub41c \ud3b8\uc9d1 \uae30\uc900(Editorial Standards)\uc744 \uc801\uc6a9\ud569\ub2c8\ub2e4. \uae30\uc5c5\uc774 \uacf5\uac1c\ud55c \ud30c\uc774\ud504\ub77c\uc778 \uc815\ubcf4\ubd80\ud130 \ub3d9\ub8cc \ud3c9\uac00\ub97c \uac70\uce5c \ud559\uc220 \ub17c\ubb38\uc5d0 \uc774\ub974\uae30\uae4c\uc9c0 \ubaa8\ub4e0 \ub370\uc774\ud130\ub97c \ub3d9\uc77c\ud55c \uae30\uc900\uc73c\ub85c \uac80\uc99d\ud574 \uc2e0\ub8b0\uc131\uc744 \ud655\ubcf4\ud569\ub2c8\ub2e4.<\/p>\n<p>\uc14b\uc9f8, \uc628\ud1a8\ub85c\uc9c0(Ontology) \uae30\ubc18 \uc778\ub371\uc2f1\uc744 \ud65c\uc6a9\ud569\ub2c8\ub2e4. \uc57d\ubb3c\uc758 \ubcc4\uce6d, \uc5f0\uad6c \ucf54\ub4dc\uba85, \ube0c\ub79c\ub4dc\uba85, \uae30\uc220\uc801 \uc124\uba85 \uc6a9\uc5b4 \ub4f1 \ub2e4\uc591\ud55c \ud45c\ud604\uc744 \ud558\ub098\uc758 \uad8c\uc704 \uc788\ub294 \uc5d4\ud130\ud2f0(Entity)\ub85c \uc5f0\uacb0\ud569\ub2c8\ub2e4. \uc774\ub7ec\ud55c \uc791\uc5c5\uc740 700\uac1c \uc774\uc0c1\uc758 \ub3d9\ub8cc \ud3c9\uac00 \ud559\uc220\uc9c0, 100\uac1c \uc774\uc0c1\uc758 \uc8fc\uc694 \ud559\ud68c, 7\uac1c \uae00\ub85c\ubc8c \ud2b9\ud5c8\uccad, \uadf8\ub9ac\uace0 FDA, EMA, PMDA, TGA \ub4f1 \uc8fc\uc694 \uaddc\uc81c\uae30\uad00\uc758 \ub370\uc774\ud130\ub97c \uc544\uc6b0\ub974\uba70 \uc218\ud589\ub429\ub2c8\ub2e4.<\/p>\n<p>\ud2b9\ud788 \uc911\uc694\ud55c \uac83\uc740 \uacfc\uac70\uc758 \uae30\ub85d\uae4c\uc9c0 \ud568\uaed8 \ubcf4\uc874\ub41c\ub2e4\ub294 \uc810\uc785\ub2c8\ub2e4.<\/p>\n<p>\uc608\ub97c \ub4e4\uc5b4 2016\ub144\uc5d0 \uc0ac\uc6a9\ub418\ub358 \uc5f0\uad6c \ucf54\ub4dc\uba85\uc740 2026\ub144\uc5d0 \uc2b9\uc778\ub41c \uc81c\ud488 \uc815\ubcf4\uc640 \uc5ec\uc804\ud788 \uc5f0\uacb0\ub429\ub2c8\ub2e4. \ub450 \ucc28\ub840 \uc774\uc0c1\uc758 \uc778\uc218\ud569\ubcd1\uc744 \uac70\uce5c \uae30\uc5c5 \uc5ed\uc2dc \uc804\uccb4 \uac1c\ubc1c \uc774\ub825\uc744 \uc720\uc9c0\ud55c \ucc44 \ucd94\uc801\ud560 \uc218 \uc788\uc2b5\ub2c8\ub2e4. \ub610\ud55c &#8220;MALT lymphoma&#8221;\ub97c \uac80\uc0c9\ud558\ub4e0 &#8220;marginal zone B-cell lymphoma&#8221;\ub97c \uac80\uc0c9\ud558\ub4e0 \ub3d9\uc77c\ud55c \uacb0\uacfc\ub97c \ud655\uc778\ud560 \uc218 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>Breyanzi(liso-cel)\uc758 \uc0ac\ub840\ub294 \uacb0\ucf54 \ud2b9\ubcc4\ud55c \uc608\uc678\uac00 \uc544\ub2d9\ub2c8\ub2e4. \uc624\ud788\ub824 Cortellis\uac00 \ucd94\uc801\ud558\ub294 10\ub9cc \uac1c \uc774\uc0c1\uc758 \uac1c\ubc1c \ud504\ub85c\uadf8\ub7a8\uc744 \uace0\ub824\ud558\uba74, \uc774\uc640 \uac19\uc740 \ubcf5\uc7a1\uc131\uc740 \uc608\uc678\uac00 \uc544\ub2c8\ub77c \uc77c\uc0c1\uc5d0 \uac00\uae5d\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uacb0\uad6d \uc81c\uc57d \uacbd\uc7c1 \uc815\ubcf4\uc758 \uac00\uce58\ub294 \ub2e8\uc21c\ud788 \ub354 \ub9ce\uc740 \ub370\uc774\ud130\ub97c \uc218\uc9d1\ud558\ub294 \ub370 \uc788\uc9c0 \uc54a\uc2b5\ub2c8\ub2e4. \uc11c\ub85c \ub2e4\ub978 \uc774\ub984\uacfc \ucf54\ub4dc, \uae30\uc5c5 \uc774\ub825, \uc801\uc751\uc99d \uc815\ubcf4\ub97c \uc815\ud655\ud558\uac8c \uc5f0\uacb0\ud574 \ud558\ub098\uc758 \uc644\uc804\ud55c \uadf8\ub9bc\uc73c\ub85c \ubcf4\uc5ec\uc8fc\ub294 \uac83, \uadf8\uac83\uc774 \uc9c4\uc815\ud55c \uc81c\uc57d \uc778\ud154\ub9ac\uc804\uc2a4\uc758 \ud575\uc2ec\uc785\ub2c8\ub2e4.<\/p>\n<p><strong><em>\uc81c\uc57d\u00b7\ubc14\uc774\uc624 \uae30\uc5c5\uc774 \uc0ac\ud6c4 \ub300\uc751 \uc911\uc2ec\uc758 \uacbd\uc7c1 \ubd84\uc11d\uc5d0\uc11c \ubc97\uc5b4\ub098 \ubbf8\ub798\ub97c \uc608\uce21\ud558\uace0 \uae30\ud68c\ub97c \uc120\uc810\ud560 \uc218 \uc788\ub3c4\ub85d <a href=\"https:\/\/clarivate.com\/life-sciences-healthcare\/ko\/portfolio-strategy\/competitive-intelligence\/cortellis-competitive-intelligence-analytics\/\">Cortellis Competitive Intelligence<\/a>\uac00 \uc5b4\ub5bb\uac8c \uc9c0\uc6d0\ud558\ub294\uc9c0 \uc54c\uc544\ubcf4\uc138\uc694.<\/em><\/strong><\/p>\n<h3><strong>\ub808\ud37c\ub7f0\uc2a4<\/strong><\/h3>\n<ol>\n<li>S. Food and Drug Administration. (2026, March 11). <em>BREYANZI<\/em>. Retrieved from www.fda.gov: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/breyanzi<\/li>\n<li>S. Securities Exchange Commission. (2018, March 6). <em>CELGENE COMPLETES ACQUISITION OF JUNO THERAPEUTICS, INC.,<\/em>. Retrieved from www.sec.gov: https:\/\/www.sec.gov\/Archives\/edgar\/data\/816284\/000114420418012947\/tv487762_99-2.htm<\/li>\n<li>American Pharmaceutical Review. (2018, March 6). <em>Celgene Completes Acquisition of Juno Therapeutics<\/em>. Retrieved from https:\/\/www.americanpharmaceuticalreview.com\/1315-News\/347745-Celgene-Completes-Acquisition-of-Juno-Therapeutics\/<\/li>\n<li>Schubert, C. (2019, January 10). <em>Bristol-Myers Squibb<\/em><em>\u2019s $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert<\/em>. Retrieved from GeekWire: https:\/\/www.geekwire.com\/2019\/bristol-myers-squibbs-74b-acquisition-juno-parent-celgene-puts-seattle-biotech-world-alert\/<\/li>\n<li>Bristol Myers Squibb. (2025, December 4). <em>Bristol Myers Squibb<\/em><em>\u2019s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)<\/em>. Retrieved from news.bms.com: https:\/\/news.bms.com\/news\/corporate-financial\/2025\/Bristol-Myers-Squibbs-Breyanzi-Approved-by-the-U-S&#8211;FDA-as-the-First-and-Only-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Marginal-Zone-Lymphoma-MZL\/default.aspx<\/li>\n<li>National Institutes of Health. (2025, August 22). <em>FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma<\/em>. Retrieved from NIH National Library of Medicine: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12369282\/<\/li>\n<li>Bristol Myers Squibb. (n.d.). <em>Breyanzi<\/em>. Retrieved from www.breyanzi.com: https:\/\/www.breyanzi.com\/<\/li>\n<li>American Association for Cancer Research. (2024). <em>Lisocabtagene Maraleucel Approved for Aggressive Lymphoma<\/em>. Retrieved from www.aacr.org: https:\/\/www.aacr.org\/patients-caregivers\/progress-against-cancer\/lisocabtagene-maraleucel-approved-for-aggressive-lymphoma\/<\/li>\n<li>Taylor, P. (2018, January 22). <em>Celgene confirms $9B Juno buyout, sees $3B sales for JCAR017<\/em>. Retrieved from Fierce Biotech: https:\/\/www.fiercebiotech.com\/biotech\/celgene-confirms-9bn-juno-buyout-sees-3bn-sales-for-jcar017<\/li>\n<li>Inman, S. (2018, January 22). <em>Celgene Acquiring Juno Therapeutics for $9 Billion<\/em>. Retrieved from OncLive: https:\/\/www.onclive.com\/view\/celgene-acquires-juno-therapeutics-for-9-billion<\/li>\n<li>S. Securities Exchange Commission. (2018, January 22). <em>CELGENE CORPORATION TO ACQUIRE JUNO THERAPEUTICS, INC., ADVANCING GLOBAL LEADERSHIP IN CELLULAR IMMUNOTHERAPY<\/em>. Retrieved from www.sec.gov: https:\/\/www.sec.gov\/Archives\/edgar\/data\/816284\/000114420418002935\/tv483707_ex99-2.htm<\/li>\n<li><em>JUNO THERAPEUTICS, INC.,<\/em>. Retrieved from www.sec.gov: https:\/\/www.sec.gov\/Archives\/edgar\/data\/816284\/000114420418012947\/tv487762_99-2.htm<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>2018\ub144 3\uc6d4, Celgene\uc740 90\uc5b5 \ub2ec\ub7ec \uaddc\ubaa8\ub85c Juno Therapeutics\ub97c \uc778\uc218\ud558\uba70 \ub2f9\uc2dc JCAR017\uc73c\ub85c \uc54c\ub824\uc9c4 CAR-T \uc138\ud3ec \uce58\ub8cc\uc81c \ud504\ub85c\uadf8\ub7a8\uc758 \uad8c\ub9ac\ub97c \ud655\ubcf4\ud588\uc2b5\ub2c8\ub2e4. \uadf8\ub9ac\uace0 1\ub144 \ub4a4\uc778 2019\ub144, Bristol Myers Squibb\uc774 Celgene\uc744 740\uc5b5 \ub2ec\ub7ec\uc5d0 \uc778\uc218\ud558\uba74\uc11c \ud574\ub2f9&#8230;<\/p>\n","protected":false},"author":318,"featured_media":583776,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_links_to":"","_links_to_type":0,"footnotes":""},"categories":[2452],"tags":[2559,2571,2960,2464,2467,2913],"class_list":["post-583821","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","tag-biopharma","tag-dealmaking","tag-ma","tag-pharma","tag-portfolio-strategy-2","tag-research-2"],"acf":[],"lang":"ko","translations":{"ko":583821,"en":583775,"ja":583820},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/583821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/users\/318"}],"replies":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/comments?post=583821"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/583821\/revisions"}],"predecessor-version":[{"id":584685,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/583821\/revisions\/584685"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media\/583776"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=583821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/categories?post=583821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/tags?post=583821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}